

# Sickle Cell Disease: Across the Lifespan

---

Susan E. Kirk, PA-C  
Instructor, Baylor College of Medicine  
Texas Children's Hematology Center  
American Academy of Physician Assistants  
Annual Conference, 2020

# Sickle Cell Disease: Across the Lifespan

## Financial Relationships

BioMarin – honoraria for non-branded speaking engagements on gene therapy

## Off-Label/Investigational Uses


None

# Sickle Cell Disease: Across the Lifespan

## Learning Objectives

1. Identify key improvements in the management of sickle cell disease for children
2. Express the challenges encountered in care of adult patients with sickle cell disease
3. Distinguish the unique features of pregnancy in women with sickle cell disease
4. Discuss the impact of appropriate medical management on health and quality of life in patients with sickle cell disease
5. Describe the current state of medical management of sickle cell disease
6. Describe future therapies that may impact the care of sickle cell disease

# An Historical Perspective



# An Historical Perspective

Dr. Herrick described sickled red blood cells in a dental student from Grenada



1910

1949



Dr. Pauling distinguished sickle hemoglobin from typical adult hemoglobin

Drs. Beet and Neel identified the single amino acid substitution on the beta globin chain

Median survival for people with SCD was 42 years for men and 48 years for women



1978 - 1988

1979



Dr. Scott described sickle cell disease as a "disease of childhood."

Median survival for people with SCD was 38 years for men and 42 years for women



1979 - 2005

2019



>95% of children survive to their 18th birthday

# What changed for children?

1975-1985: Newborns screening positive for sickle cell disease were incorporated into a comprehensive sickle cell center

## PARENTS WERE TAUGHT:



- Fever management
- Spleen palpation
- When to seek medical attention

OVERALL MORTALITY DROPPED FROM 8% TO **1.8%**



# Contributions to child health



## PROPS Trial (1988)

Penicillin prophylaxis is effective in preventing pneumococcal sepsis



Vaccines against encapsulated bacteria



## STOP Trial (1998)

Transcranial doppler ultrasound screening for stroke and chronic transfusions to prevent primary stroke



## BABY HUG Trial (2011)

Hydroxyurea safe and effective in children

Let's all think back...

Baylor  
College of  
Medicine





# Living to Adulthood



# Sickle Cell Trait and Disease: The Numbers



Babies with SCD  
born in the US each  
year

**1:12**

Black Americans have  
S trait

**1:150**

Hispanic Americans  
have S trait




Babies born each  
year with sickle cell  
disease globally



# Genetics of SCD

Chromosome 11



Valine → Glutamine

Autosomal Recessive



Must have two abnormal copies to result in disease

Genotypes

AA: "Normal" hemoglobin



AS: Sickle cell trait



SS: Sickle cell disease



Other beta globin traits:

C trait (AC)

$\beta^0$  trait ( $A\beta^0$ )


$\beta^+$  trait ( $A\beta^+$ )



---

# Genetics of Sickle Cell


---




---

# Genetics of Sickle Cell

---



AA




AS

---

# Genetics of Sickle Cell

---



---

# Genetics of Sickle Cell

---



My partner has sickle cell trait. Is it possible for us to have a baby with sickle cell disease?



# Testing for sickle cell disease



## Newborn Screen

Pros: early detection, most beta traits and disease states detected

Cons: misses beta thal traits



## Hemoglobin Profile

Pros: most hemoglobin traits and disease states detected

Cons: should be run >6 months of age; inaccurate after transfusion



## Genetic Testing

Pros: able to give exact variant for complex cases


Cons: expensive, results take weeks-months



## Sickle Dex

Pros: I'm not sure

Cons: does not differentiate between S trait and disease, only detects S




---

# Genetics of Sickle Cell


---

# Peripheral Blood Smears




<http://imagebank.hematology.org/image/3666/normal-peripheral-blood-smear-1?type=upload>

Normal



[http://dx.doi.org/10.1016/S0140-6736\(10\)61029-X](http://dx.doi.org/10.1016/S0140-6736(10)61029-X)

Hemoglobin SS



Source: Lichtman MA, Shafer MS, Felgar RE, Wang N: *Lichtman's Atlas of Hematology*: <http://www.accessmedicine.com>

Hemoglobin SC

# Morbidities in Adulthood




Age 25:  
second stroke peak




Acute Chest  
Pulmonary Hypertension



Functional  
Hyposplenism



Left Ventricle  
Dysfunction



Renal Failure  
Decreased Epo




Organ Ischemia

# Reproductive Health

- ① Limited contraceptive options
- ② Safety of medications during pregnancy largely unknown
- ③ Role of transfusions during pregnancy is unclear

Increased risks with Pregnancy in Women with SCD





## Neonates

4x risk of stillbirth

Neonatal  
alloimmunization due  
to maternal RBC  
antibodies




## Male Health

Hypogonadism due to  
testicular infarcts

Erectile dysfunction  
due to priapism



# STIGMA



# How do you know if someone is in pain?



# How do you know if someone is in pain?



Gross visualization



Laboratory or imaging



Verbalization

# What is chronic pain?

"...pain standing in my way of doing something I want to do."

"I would love to be working, driving a car...have what regular folks have...a family, get married."

"A daily thing...it's a constant battle everyday."

"I'm still fighting depression all the time."

"I changed doctors...with the hopes of finding someone who would listen to my symptoms and do more than just throw pain medicine at me."

"Self-management of chronic pain is a priority, a full-time job, a full-time child, a full-time life."

# Managing Chronic Pain

## Individual Factors

Knowing personal triggers  
Sites of previous pain events

## Pharmacotherapy

Opioids may not be part of a  
chronic pain treatment plan

## Psychology

Recognizing and treating  
underlying depression or  
anxiety

## Utilizing Healthcare

Positive interactions with  
primary and emergency  
providers

## Lifestyle

Maintaining productive and  
active lifestyle

## Connections


Talking with others who  
manage their chronic pain




# Addressing the Stigma

- ① Healthcare provider perceptions and treatment influence outcomes in SCD
- ② Education is the key  
As little as 90 minutes of education for pediatric residents improved empathy for SCD
- ③ Opioids and addiction  
1998-2013  
Non-SCD: Mortality rates due to opioids increased by 350%  
SCD: No increase in mortality due to opioids


## Emergency Department (ED) Visits Among People with Sickle Cell in California, 2005-2014



# The Adolescent and Young Adult



# SCD Related Mortality in the US (1999-2009)



# Comprehensive Care Model



NIH recommends: 1 physician, >1 APP, a health educator, and a medical social worker at a facility with lab/radiology services and a 24-hour blood bank

- 1 Create an individualized "Pain Plan" for every patient
- 2 Increase communication between primary and specialty providers
- 3 Create multi-disciplinary teams in EDs to treat pain



**A national poll in 2016 found that \_\_\_\_% of primary care providers were comfortable in treating sickle cell disease?**

- A. 5%
- B. 20%
- C. 40%
- D. 60%
- E. 80%

A national poll in 2016 found that \_\_\_\_% of primary care providers were comfortable in treating sickle cell disease?

- A. 5%
- B. 20%**
- C. 40%
- D. 60%
- E. 80%



**20%**

# Treatments for SCD

## Hydroxyurea (Hydrea<sup>®</sup>)

### Pros:

- minimal side effects
- once daily oral
- preventative
- cheap
- long-term use studied

### Cons:

- requires lab monitoring
- variable response

FDA approved:  $\geq 18$  years in 1998  
 $\geq 2$  years in 2017

## Voxelotor (Oxbryta<sup>™</sup>)

### Pros:

- once daily oral
- no lab monitoring
- long-term use being monitored

### Cons:

- expensive
- moderate side effects

FDA approved:  $\geq 12$  years in 2019

## Crizanlizumab (Adakveo<sup>®</sup>)

### Pros:

- quick infusion
- once monthly dosing
- well-tolerated
- long-term use being monitored

### Cons:

- requires monthly infusion visits
- expensive


FDA approved:  $\geq 16$  years in 2019

## Others

L-glutamine (Endari<sup>®</sup>): FDA approved  $\geq 5$  years in 2017

Rivipansel (GMI-1070): failed to meet primary endpoint in Phase 3

# Effects of Hydroxyurea



<http://www.bloodjournal.org/content/115/26/5300?sso-checked=true>



# Future Directions

- ① Improving therapies for prevention and treatment of complications
- ② Tackling the global burden of sickle cell
- ③ Improving outcomes of stem cell transplant
- ④ Perfecting gene therapy

# Your role in treating sickle cell disease

---

**Educate** yourself and others on the impact that appropriate medical management can have on patients' quality of life and health status.

**Identify** other providers in your community who are interested in sickle cell disease and keep lines of communication open.

**Research** current and updated options for treatment of sickle cell disease.

**Educate** your patients on their disease, their pain management strategies, their goals for care

**Advocate** for the patient with sickle cell disease.

# Resources

American Society of Hematology Guidelines (2019):

<https://www.hematology.org/Clinicians/Guidelines-Quality/Guidelines.aspx#scd>

National Heart, Lung and Blood Institute Guidelines (2014):

<https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/evidence-based-management-sickle-cell-disease-expert-0>

Center for Disease Control Fact Sheet for Emergency Room:

[https://www.cdc.gov/ncbddd/sicklecell/documents/Sickle\\_Cell\\_Providers.pdf](https://www.cdc.gov/ncbddd/sicklecell/documents/Sickle_Cell_Providers.pdf)

Nursing implications for Sickle Cell Disease:

[https://www.cdc.gov/ncbddd/sicklecell/documents/Sickle\\_Cell\\_Providers.pdf](https://www.cdc.gov/ncbddd/sicklecell/documents/Sickle_Cell_Providers.pdf)

# References

- Chaturvedi S, DeBaun MR. Evolution of sickle cell disease from a life-threatening disease of children to a chronic disease of adults: The last 40 years. *Am J Hematol*. 2016;91:5-14.
- Davis H, Schoendorf KC, Gergen PJ, Moore RM. National trends in the mortality of children with sickle cell disease, 1968 through 1992. *Am J Public Health*. 1997;87:1317-1322.
- Yanni E, Crosse SD, Yang Q, Olney RS. Trends in pediatric sickle cell disease-related mortality in the United States, 1983-2002. *J Ped*. 2009;154(4):541-545.
- McLaughlin JF, Ballas SK. High mortality among children with sickle cell anemia and overt stroke who discontinue blood transfusion after transition to an adult program. *Transfusion*. 2016;56:1014-1021.
- Serjeant, GR. The natural history of sickle cell disease. *Cold Spring Harb Perspect Med*. 2013;3:a011783.
- Platt OS, Brambilla DJ, et al. Mortality in sickle cell disease. *N Engl J Med*. 1994;330:1639-44.
- Rizk S, Pulte ED, Axelrod D, Ballas SK. Perinatal maternal mortality in sickle cell anemia: two case reports and review of the literature. *Hemoglobin*. 2017; 41:4-6, 225-229.
- Vichinsky E, Hurst D, Earles A, et al. Newborn screening for sickle cell disease: Effect on mortality. *Pediatrics*. 1988;81:749-755.



# References

Porter JS, Wesley KM, et al. Pediatric to adult care transition: Perspectives of young adults with sickle cell disease. *Journal of Pediatric Psychology*. 2017;42(9):1016-1027.

Cappelli B, Volt F, et al. Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease. *Haematologica*. 2019;e104-xxx.

Calhoun CL, Abel RA, Pham HA, Thompson S, King AA. Implementation of an education intervention to optimize self-management and transition readiness in young adults with sickle cell disease. *Pediatr Blood Cancer*. 2019;66:e27722.

Lanzkron S, Carroll CP, Haywood C. Mortality rates and age at death from sickle cell disease: U.S., 1979-2005. *Public Health Reports*. 2013;128:110-116.

Oteng-Ntim E. Pregnancy in women with sickle cell disease is associated with risk of maternal and perinatal mortality and severe morbidity. *Evid Based Nurs*. 2017;20(2):43.

Liu L, Ozo S, Hogan D, et al. Global, regional and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. *Lancet*. 2015;385:430-439.

Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle cell anaemia: A multicentre, randomized, controlled trial. *Lancet*. 2011;377:1663-1672.

Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. *N Engl J Med*. 1998; 339:5-11.

# Thank You

Thank you for your attention and staying until the end.  
Please stay safe and healthy.

Please feel free to email me for any questions at  
[sekirk@bcm.edu](mailto:sekirk@bcm.edu).